Avacta has moved to shoot down a report from the HuffPost UK which indicated that the government had selected its COVID-19 rapid antigen test and was in the final phases of evaluation by Porton Down.
The report soon found itself in a number of media outlets included the Daily Mail over the weekend.
In an update entitled ‘Re: Press Speculation’, Avacta noted the report was incorrect:
“The press report this weekend incorrectly stated that a saliva-based rapid antigen test from Avacta had been evaluated at Porton Down. In fact, the evaluated test was the anterior nasal swab test that has subsequently generated the excellent initial clinical performance data outlined above. However, in its evaluation Porton Down used artificial samples and did not use clinical samples.”
However it added that while it is not the rapid antigen test that is currently being evaluated by the government, it believes in the importance of an accurate test and that it continues to be in dialogue with the government and other parties:
“While Avacta continues to be in dialogue with the DHSC, and with other organisations in the UK and abroad, with a view to future supply of its rapid antigen test, it is prioritising the full clinical validation of its nasal swab-based SARS-CoV-2 rapid antigen test as a pre-requisite for CE marking and broad commercialisation.”
It added that it will update the market fully through appropriate channels when both technical and commercial milestones are achieved.
The HuffPost UK also drew reference to Omega Diagnostics and Mologic in its article.